




Czechia GLP-1

Jakub Velík
SÚKL, Czechia


02.07.2024

GLP-1


Very specific medicine category due high level of interest of physician to initiate new treatment, high number of treated patient, social media reports of off-label use, media coverage, occurrence of falsified medicines in the EU,.....





Total GLP-1 supply (A10BJ) in volume (packs) + Shortages



Total GLP-1 supply (A10BJ) in volume (packs) + Shortages + Mitigation measures



Total GLP-1 supply (A10BJ) in volume (packs) + Shortages + Mitigation measures



Summary

- 👁 Communication between authorities and MAHs are crucial
- 👁 For dynamic areas, like GLP-1, it is necessary to rationally estimate the future need and development of the market
- 👁 MAH must carefully plan production and allocations to avoid shortage more than 2 weeks
- 👁 If there is a need to intervene in the functioning of the market, transparency and discussions with learned societies is appropriate
- 👁 Our experience shows that timely, targeted and broadly communicated restrictive measures can positively influence market dynamics and improve the availability of medicines



Thank you for you attention!